A recent study by Nutanix has highlighted the accelerated adoption of Generative AI (GenAI) and containerization within the healthcare sector, while also identifying significant challenges in the modernization of IT infrastructure needed to support these technologies. According to the report, 99% of healthcare organizations are leveraging GenAI applications, yet nearly all face data security and integration challenges when scaling these workloads. The study emphasizes the necessity for enhanced data governance and modernized infrastructure to fully realize the benefits of GenAI, given its critical impact on patient outcomes. Additionally, the expansion of containerization and Kubernetes deployments is noted as a significant trend accommodating the growing cloud native applications.
- Nutanix (NasdaqGS:NTNX) last closed at $76.80 up 1.8%.
In other market news, Datadog (NasdaqGS:DDOG) was trading firmly up 14.9% and ending trading at $155.15. Meanwhile, VMware (NYSE:VMW) lagged, down 5% to close at $142.48.
Best Cloud AI Stocks
- Microsoft (NasdaqGS:MSFT) settled at $498.84 up 1.6%, not far from its 52-week high. In the past three days, Microsoft advanced strategic collaborations focusing on AI healthcare solutions, enterprise content management, and data security with Lunit, M-Files, and Varonis.
- Apple (NasdaqGS:AAPL) finished trading at $213.55 up 0.5%.
- Alphabet (NasdaqGS:GOOGL) finished trading at $179.53 up 0.5%.
Next Steps
- Click here to unveil our expertly curated list of 167 Cloud AI Stocks including EPAM Systems, AppFolio and Hexaware Technologies.
- Curious About Other Options? AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Sources:
Valuation is complex, but we're here to simplify it.
Discover if Alphabet might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com